![Gary Lee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gary Lee
Chief Tech/Sci/R&D Officer at
LYELL IMMUNOPHARMA, INC.
Net worth: 232 270 $ as of 31/08/2026
Profile
Gary Lee is currently Chief Scientific Officer at Lyell Immunopharma, Inc. since 2022.
Formerly, Dr. Lee was Vice President-Cell Therapy at Sangamo Therapeutics, Inc. from 2005 to 2018 and Chief Scientific Officer at Senti Sub I, Inc. from 2018 to 2022.
Education includes undergraduate studies at California Institute of Technology and a doctorate from the University of California, Berkeley.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/08/2026 | 16,220 ( 0.07% ) | 232 270 $ | 31/08/2026 |
Gary Lee active positions
| Companies | Position | Start |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 31/01/2022 |
Former positions of Gary Lee
| Companies | Position | End |
|---|---|---|
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Chief Tech/Sci/R&D Officer | 01/01/2022 |
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2018 |
Training of Gary Lee
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
- Stock Market
- Insiders
- Gary Lee
